MITOMETIN

Amyotrophic Lateral Sclerosis (ALS)

Pathology shared with Parkinson's disease, multiple sclerosis,  and Alzheimer's disease

Fully owned. Composition-of-matter patents filed in 2022; protection to 2042+.

Mechanism

Selective CPT1A inhibition — restores glucose oxidation, reduces excessive fatty-acid oxidation and ROS.

Unmet medical need & differentiation

• ALS progresses rapidly with ~50% mortality within 2 years; current treatments offer only modest survival benefit and no meaningful disease modification.
• Neurometa targets neurometabolic dysregulation via CPT1A inhibition, a genetically validated pathway and core hallmark of ALS that remains unexplored by other therapies.
• Our first-in-class CPT1A inhibitor for neurodegeneration is clearly differentiated from other approaches.
• We are developing an oral small molecule with potential to become the new standard of care by addressing a fundamental, untargeted driver of disease.

SOSIN

Neurofibromatosis Type 1 (NF1)

Pain (NIH HEAL Initiative)

Exclusive worldwide license. Composition-of-matter patents on lead (2022) and back-up (2025) series.

Mechanism

SOS1 inhibition upstream of MEK — directly reduces RAS activation at the root of pathway hyperactivity.

Unmet medical need & differentiation

• High unmet need in NF1: debilitating nerve tumors and pain with only two approved MEK inhibitors, both limited by significant side effects and high discontinuation rates.
• More than 130,000 people living with NF1 in the 7 major markets with blockbuster potential.
• Novel SOS1 inhibitor acting upstream in the validated RAS/MEK pathway.
• Differentiated by potentially avoiding MEK class toxicities while maintaining efficacy on tumor growth.

HEATMOD

Neuroinflammation & Autoimmunity

Broad blockbuster potential across neurology and immunology

Fully owned. AI-driven target and compound modeling led by the Neurometa team.

Mechanism

Modulation of extracellular HSP70 — promotes tolerogenic, not suppressed, immunity.

Unmet medical need & differentiation

• Most current therapies rely on broad immunosuppression with serious long-term risks.
• Neurometa is developing a first-in-class small molecule drug that induces antigen-specific immune tolerance by modulating extracellular HSP70i signaling.
• Clearly differentiated from broad immunosuppressants and cell-based tolerance strategies; no approved drugs currently achieve antigen-specific tolerance.
• Potential to transform treatment by replacing non-specific suppression with targeted immune reprogramming.